Related Experiment Video
Updated: Nov 11, 2025
Quantification and Whole Genome Characterization of SARS-CoV-2 RNA in Wastewater and Air Samples
Published on: June 30, 2023
Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway
Andrea R Daamen1, Prathyusha Bachali2, Katherine A Owen2
1AMPEL BioSolutions LLC, Charlottesville, VA, 22902, USA. andrea.daamen@ampelbiosolutions.com.
Abstract:
SARS-CoV2 is a previously uncharacterized coronavirus and causative agent of the COVID-19 pandemic. The host response to SARS-CoV2 has not yet been fully delineated, hampering a precise approach to therapy. To address this, we carried out a comprehensive analysis of gene expression data from the blood, lung, and airway of COVID-19 patients. Our results indicate that COVID-19 pathogenesis is driven by populations of myeloid-lineage cells with highly inflammatory but distinct transcriptional signatures in each compartment. The relative absence of cytotoxic cells in the lung suggests a model in which delayed clearance of the virus may permit exaggerated myeloid cell activation that contributes to disease pathogenesis by the production of inflammatory mediators. The gene expression profiles also identify potential therapeutic targets that could be modified with available drugs. The data suggest that transcriptomic profiling can provide an understanding of the pathogenesis of COVID-19 in individual patients.
Insights
COVID-19 pathogenesis involves inflammatory myeloid cells in blood, lung, and airway. Transcriptomic profiling reveals distinct cell signatures and potential therapeutic targets for SARS-CoV-2 infection.
Area of Science:
- Immunology
- Genomics
- Infectious Diseases
Background:
- The host response to SARS-CoV-2, the virus causing COVID-19, is not fully understood.
- This knowledge gap hinders the development of targeted therapies.
Purpose of the Study:
- To comprehensively analyze gene expression data from COVID-19 patients.
- To delineate the host response and identify therapeutic targets.
Main Methods:
- Analysis of gene expression data from blood, lung, and airway samples of COVID-19 patients.
- Identification of distinct transcriptional signatures in myeloid-lineage cells.
Main Results:
- COVID-19 pathogenesis is driven by inflammatory myeloid cells with unique signatures in different body compartments.
- A relative absence of cytotoxic cells in the lung may lead to delayed viral clearance and exaggerated myeloid cell activation.
- Production of inflammatory mediators by activated myeloid cells contributes to disease pathogenesis.
Conclusions:
- Transcriptomic profiling provides insights into COVID-19 pathogenesis at an individual patient level.
- Distinct myeloid cell populations and their inflammatory signatures are key to understanding COVID-19.
- Identified gene expression profiles suggest potential therapeutic targets for COVID-19 treatment.
